NCT04639739

Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

Status unknown EARLY_PHASE1 Last updated 20 November 2020

What this trial tests

EARLY_PHASE1 trial testing anti-CD19 CAR NK in NHL in 9 participants. Status unknown.

Timeline

17 December 2020

Primary endpoint
1 December 2021

1 December 2023

Quick facts

Lead sponsor	Xinqiao Hospital of Chongqing
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	17 December 2020
Primary completion	1 December 2021
Estimated completion	1 December 2023
Sites	1 location across China

Drugs / interventions tested

• anti-CD19 CAR NK — full drug profile →

Conditions studied

• NHL — all drugs for NHL →

Sponsor

Xinqiao Hospital of Chongqing

Who can join

Adults 18 to 75, any sex, with NHL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are limitations of CAR-T cells, the consuming manufacturing time and expensive price exclude the majority of patients. therefore, we designed this trial to manifest the safety and efficacy of anti-CD19 CAR NK cell therapy in non-Hodgkin lymphoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Natural killer cells in antitumour adoptive cell immunotherapy.
   Laskowski TJ, Biederstädt A, Rezvani K. · · 2022 · cited 547× · PMID 35879429 · DOI 10.1038/s41568-022-00491-0
2. Exploring treatment options in cancer: Tumor treatment strategies.
   Liu B, Zhou H, Tan L, Siu KTH, et al · · 2024 · cited 536× · PMID 39013849 · DOI 10.1038/s41392-024-01856-7
3. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
   Pan K, Farrukh H, Chittepu VCSR, Xu H, et al · · 2022 · cited 478× · PMID 35361234 · DOI 10.1186/s13046-022-02327-z
4. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
   Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, et al · · 2021 · cited 293× · PMID 33933160 · DOI 10.1186/s13045-021-01083-5
5. Natural killer cell homing and trafficking in tissues and tumors: from biology to application.
   Ran GH, Lin YQ, Tian L, Zhang T, et al · · 2022 · cited 207× · PMID 35768424 · DOI 10.1038/s41392-022-01058-z
6. CAR-NK cells for cancer immunotherapy: from bench to bedside.
   Zhang L, Meng Y, Feng X, Han Z. · · 2022 · cited 144× · PMID 35303962 · DOI 10.1186/s40364-022-00364-6
7. Natural killer cells: a promising immunotherapy for cancer.
   Chu J, Gao F, Yan M, Zhao S, et al · · 2022 · cited 140× · PMID 35606854 · DOI 10.1186/s12967-022-03437-0
8. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
   Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, et al · · 2022 · cited 125× · PMID 36348457 · DOI 10.1186/s13045-022-01382-5